A5079519216- Cystic Fibrosis Research Advances
- Family and Disability Support Research
- Palliative Care and End-of-Life Issues
- Child Nutrition and Feeding Issues
- Adolescent and Pediatric Healthcare
- Attention Deficit Hyperactivity Disorder
- Child and Adolescent Psychosocial and Emotional Development
- Family and Patient Care in Intensive Care Units
- Geriatric Care and Nursing Homes
- Maternal Mental Health During Pregnancy and Postpartum
- Infant Development and Preterm Care
- Bipolar Disorder and Treatment
- Impact of Technology on Adolescents
- Child Development and Digital Technology
- Asthma and respiratory diseases
- Childhood Cancer Survivors' Quality of Life
- Breastfeeding Practices and Influences
- Pediatric health and respiratory diseases
- Patient Dignity and Privacy
- Digital Mental Health Interventions
- Health Policy Implementation Science
- Maternal and Perinatal Health Interventions
- Personality Disorders and Psychopathology
- Family Caregiving in Mental Illness
- Neonatal Respiratory Health Research
Massachusetts General Hospital
2016-2025
Harvard University
2010-2023
Boston University
2005-2023
RELX Group (Netherlands)
2012
University of Pittsburgh
2008-2009
VA Pittsburgh Healthcare System
2009
WinnMed
1999-2001
Mayo Clinic
1999-2001
Studies measuring psychological distress in individuals with cystic fibrosis (CF) have found high rates of both depression and anxiety. Psychological symptoms CF parent caregivers been associated decreased lung function, lower body mass index, worse adherence, health-related quality life, more frequent hospitalisations increased healthcare costs. To identify treat anxiety CF, the Foundation European Society invited a panel experts, including physicians, psychologists, psychiatrists, nurses,...
Although certain media exposures have been linked to the presence of psychiatric conditions, few studies investigated association between exposure and depression.To assess longitudinal in adolescence depression young adulthood a nationally representative sample.Longitudinal cohort study.We used National Longitudinal Survey Adolescent Health (Add Health) investigate relationship electronic 4142 adolescents who were not depressed at baseline subsequent development after 7 years follow-up. Main...
This is the second in a series of four papers updating European Cystic Fibrosis Society (ECFS) standards for care people with CF. paper focuses on establishing and maintaining health. The guidance produced using an evidence-based framework wide stakeholder engagement, including from CF community. Authors provided narrative description their topic statements, which were more directive. These statements reviewed by Delphi exercise, achieving good levels agreement group all statements....
Abstract Introduction Reports of neuropsychiatric symptoms proximal to cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation are emerging, but their prevalence and management remain poorly characterized. Methods Retrospective chart review was used categorize symptom trajectories all adults at a single CF Center who initiated elexacaftor/tezacaftor/ivacaftor (ETI) before March 2022 subsequently had ≥1 outpatient visit with the consulting psychiatrist. For those...
Abstract Background Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with unprecedented clinical improvements, transforming the management of cystic fibrosis (CF). However, side effects implications for safety and well‐being have reported, including neuropsychiatric changes. This study aimed to better characterize emerging positive negative impacts ETI. Methods The Cystic Fibrosis Foundation's Mental Health Advisory Committee distributed a 26‐item survey US CF care teams assess...
BackgroundPeople with cystic fibrosis (PwCF) have experienced substantial improvements in health following use of transmembrane conductance regulator (CFTR) modulator therapies. However, less is known about how therapies impact well-being.MethodsWe used a cross-sectional observational study to identify relationships between CFTR therapies, health-related quality life (HRQoL), and well-being. Adult PwCF caregivers children CF completed the Wellness Modulator Era (Well-ME) survey June 22 July...
To estimate the community prevalence in Olmsted County, Minnesota of elevated scores on Edinburgh Postnatal Depression Scale, a self-report screening tool for postpartum depression.At 6-week visit, Scale was administered to women who gave birth County between July 28, 1997 and March 1998. Study sites included all ambulatory clinics that provide pregnancy care county, missed visits were contacted by mail. A threshold 12 or more points scale selected clinical use; data ten above also...
Aim: To evaluate the safety and efficacy of lamotrigine monotherapy as an acute treatment bipolar mood elevation in children with spectrum disorders. Method: This was a 12‐week, open‐label, prospective trial to assess effectiveness tolerability this compound treating pediatric disorder. Assessments included Young Mania Rating Scale (YMRS), Clinical Global Impressions‐Improvement scale (CGI‐I), Children's Depression (CDRS), Brief Psychiatric (BPRS). Adverse events were assessed through...
Cystic fibrosis (CF) affects more than 70,000 individuals and their families worldwide. Although outcomes for with CF continue to improve, it remains a life-limiting condition no cure. Individuals manage extensive symptom treatment burdens face complex medical decisions throughout the illness course. palliative care has been shown reduce suffering by alleviating illness-related people serious families, little is known regarding components structure of various delivery models needed improve...
Depression and anxiety are two to four times more prevalent in people with CF (pwCF) than the general population. COVID-19 may exacerbate mental health challenges, increasing demand for psychological services, while decreasing their availability. We assessed impact of pandemic on depression pwCF, including how affected frequency screening types services provided.A 38-item internet survey, completed June 2020, affected: 1) clinician's role processes; 2) barriers resource needs; 3) anxiety, 4)...
The aim of this study was to evaluate the tolerability adding OROS methylphenidate (MPH) children who are partial responders atomoxetine (ATMX) in treatment attention-deficit/hyperactivity disorder (ADHD).This a two-phase, 7-week, open aged 6-17 years. Phase 1 initiated ATMX for minimum 4 weeks. 2 entered and added MPH their regimen. Safety assessed using blood pressure heart rate measurements, electrocardiogram readings, AEs, laboratories, levels.Fifty subjects were received combination...
Objective: The aim of this study was to evaluate the safety and efficacy extended release carbamazepine (CBZ-ER) monotherapy in treatment pediatric bipolar disorder (BD). Method: This an 8-week, open-label, prospective trial CBZ-ER (788 ± 252 mg/day) assess effectiveness tolerability compound treating spectrum disorders. Assessments included Young Mania Rating Scale (YMRS), Clinical Global Impressions–Improvement scale, Children's Depression Scale, Brief Psychiatric Scale. Adverse events...
Individuals with cystic fibrosis (CF) are at increased risk for anxiety and depression, negative consequences adherence, health, quality of life. New approaches to prevent treat depression that tailored the concerns this population needed. A CF-specific internet-based cognitive-behavioral therapy (CBT) intervention was developed increase access evidence-based mental health care decrease cost burden people CF.To evaluate usability acceptability "eHealth CF-CBT," an program integrating...